A

Disease-free survival

normal (n=144, 11 lost to follow-up)

abnormal (n=11, 2 lost to follow-up)

P =0.926

SCC

Follow-up (months)

Overall survival

normal (n=144, 11 lost to follow-up)

abnormal (n=11, 2 lost to follow-up)

P =0.765

SCC

Follow-up (months)

B

Disease-free survival

abnormal (n=1, 1 lost to follow-up)

normal (n=204, 16 lost to follow-up)

P =0.769

AFP

Follow-up (months)

Overall survival

abnormal (n=1, 1 lost to follow-up)

normal (n=204, 16 lost to follow-up)

P =0.788

AFP

Follow-up (months)

C

Disease-free survival

abnormal (n=2, 1 lost to follow-up)

normal (n=203, 16 lost to follow-up)

P =0.705

CA153

Follow-up (months)

Overall survival

abnormal (n=2, 1 lost to follow-up)

normal (n=203, 16 lost to follow-up)

P =0.762

CA153

Follow-up (months)

D

Disease-free survival

normal (n=75, 2 lost to follow-up)

abnormal (n=5, 0 lost to follow-up)

P =0.139

CA199

Follow-up (months)

Overall survival

normal (n=75, 2 lost to follow-up)

abnormal (n=5, 0 lost to follow-up)

P =0.035

CA199

Follow-up (months)

Supplementary Figure S1. Kaplan–Meier curves show the association of aberrant expression of SCC, AFP, CA153 and CA199 with patient disease-free survival (DFS) and overall survival (OS). The expression of SCC (A), AFP (B), CA153(C) and CA199(D) was not significantly associated with DFS or OS.

Supplementary Tables S1 The Correlation between Expression of Tumor markers (SCC-Ag, AFP, CA153 and CA199) and Clinicopathological Characteristics in Patients with Early-stage Cervical Adenocarcinoma Characteristics.

	SCC-Ag,n(%)		P	AFP,n(%)		P	CA153,n(%)		P	CA199,n(%)		P
	abnormal	normal		abnormal	normal		abnormal	normal		abnormal	normal	
Patient age(year)			0.183			1.000			1.000			0.329
<50	10(6.5)	96(61.9)		1(0.5)	143(69.8)		2(1.0)	142(69.3)		2(2.5)	51(63.8)	
≥50	1(0.6)	48(31.0)		0(0.0)	61(29.8)		0(0.0)	61(29.8)		3(3.8)	24(30.0)	
FIGO stage			0.708			0.102			0.195			0.330
I	9(5.8)	130(83.9)		0(0.0)	184(89.8)		1(0.5)	183(89.3)		4(5.0)	70(87.5)	
II	2(1.3)	14(9.0)		1(0.5)	20(9.8)		1(0.5)	20(9.8)		1(1.2)	5(6.2)	
BMI			0.131			1.000			0.422			1.000
≤24.9	6(3.9)	114(73.5)		1(0.5)	155(75.6)		1(0.5)	155(75.6)		4(5.0)	61(76.2)	
>24.9	5(3.2)	30(19.4)		0(0.0)	49(23.9)		1(0.5)	48(23.4)		1(1.2)	14(17.5)	
Menopause			1.000			0.137			1.000			0.497
Yes	1(0.6)	20(12.9)		1(0.5)	27(13.2)		0(0.0)	28(13.7)		1(1.2)	9(11.2)	
No	10(6.5)	124(80.0)		0(0.0)	177(86.3)		2(1.0)	175(85.4)		4(5.0)	66(82.5)	
Differentiation			1.000			1.000			0.212			0.076
Well/moderate	10(6.5)	130(83.9)		1(0.5)	181(88.3)		1(0.5)	181(88.3)		3(3.8)	69(6.2)	
Poor	1(0.6)	14(9.0)		0(0.0)	23(11.2)		1(0.5)	22(10.7)		2(2.5)	6(7.5)	
Tumor size(cm)			0.723			1.000			0.272			1.000
<4	8(5.2)	118(76.1)		1(0.5)	174(84.9)		1(0.5)	174(84.9)		4(5.0)	60(75.0)	
≥4	3(1.9)	26(16.8)		0(0.0)	30(14.6)		1(0.5)	29(14.1)		1(1.2)	15(18.8)	
Myometrial invasion			1.000			0.273			0.074			0.019*
<2/3	8(5.2)	106(68.4)		0(0.0)	149(72.7)		0(0.0)	149(72.7)		1(1.2)	57(71.2)	
≥2/3	3(1.9)	38(24.5)		1(0.5)	55(26.8)		2(1.0)	54(26.3)		4(5.0)	18(22.5)	
Vaginal wall extension			0.532			0.059			1.000			0.001*
No	10(6.5)	135(87.1)		0(0.0)	193(94.1)		2(1.0)	191(93.2)		2(2.5)	73(91.2)	
Yes	1(0.6)	9(5.8)		1(0.5)	11(5.4)		0(0.0)	12(5.9)		3(3.8)	2(2.5)	
Parametrial extension			1.000			0.020*			1.000			0.062
No	11(7.1)	140(90.3)		0(0.0)	201(98.0)		2(1.0)	199(97.1)		4(5.0)	75(93.8)	
Yes	0(0.0)	4(2.6)		1(0.5)	3(1.5)		0(0.0)	4(2.0)		1(1.2)	0(0.0)	
Endometrial extension			1.000			0.054			1.000			0.009*
No	11(7.1)	138(89.0)		0(0.0)	194(94.6)		2(1.0)	192(93.7)		3(3.8)	74(92.5)	
Yes	0(0.0)	6(3.9)		1(0.5)	10(4.9)		0(0.0)	11(5.4)		2(2.5)	1(1.2)	
LVSI			0.232			0.073			0.141			1.000
No	9(5.8)	133(85.8)		0(0.0)	190(92.7)		1(0.5)	189(92.2)		5(6.2)	70(87.5)	
Yes	2(1.3)	11(7.1)		1(0.5)	14(6.8)		1(0.5)	14(6.8)		0(0.0)	5(6.2)	
LNM			0.708			0.102			0.195			0.095
No	9(5.8)	130(83.9)		0(0.0)	184(89.8)		1(0.5)	183(89.3)		3(3.8)	68(85.0)	
Yes	2(1.3)	14(9.0)		1(0.5)	20(9.8)		1(0.5)	20(9.8)		2(2.5)	7(8.8)	
Surgical margin			1.000			1.000			1.000			0.122
Clear	11(7.1)	142(91.6)		1(0.5)	202(98.5)		2(1.0)	201(98.0)		4(5.0)	74(92.5)	
Involved	0(0.0)	2(1.3)		0(0.0)	2(1.0)		0(0.0)	2(1.0)		1(1.2)	1(1.2)	

Histological type			0.004*			1.000			1.000			1.000
Pure adenocarcinoma	5(3.2)	122(78.7)		0(0.0)	36(17.6)		0(0.0)	36(17.6)		1(1.2)	17(21.2)	
Other	6(3.9)	22(14.2)		1(0.5)	168(82.0)		2(1.0)	167(81.5)		4(5.0)	58(72.5)	

Note: *Significant differences (P < 0.05) of the associations between prognostic value and disease-free and overall survival rates in patients with early-stage cervical adenocarcinoma.

Abbreviation: FIGO, International Federation of Gynecology and Obstetrics; BMI, body mass index; LVSI, lymph vascular space invasion; LNM, lymph node metastasis.